Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer

Inclusion Criteria: * Histologically confirmed endometrial adenocarcinoma * Recurrent or persistent disease * Refractory to curative therapy or established treatments * The following epithelial cell types are eligible: * Endometrioid adenocarcinoma * Serous adenocarcinoma * Undifferentiated carcinoma * Clear cell adenocarcinoma * Mixed epithelial carcinoma * Adenocarcinoma not otherwise specified * Mucinous adenocarcinoma * Squamous cell carcinoma * Transitional cell carcinoma * Mesonephric carcinoma * Measurable disease, defined as ≥1 lesion that can be accurately measured in ≥ 1 dimension as ≥ 20 mm by conventional techniques, including palpation, plain x-ray, CT scan, or MRI OR as ≥ 10 mm by spiral CT scan * Must have ≥ 1 target lesion * Tumors within a previously irradiated field are designated as target lesions provided there is documented disease progression or biopsy confirmed persistent disease ≥ 90 days after completion of radiotherapy * Must have received 1 prior chemotherapeutic regimen for management of endometrial cancer * Initial treatment may have included non-cytotoxic agents or high-dose therapy, consolidation therapy, or extended therapy administered after surgical or non-surgical assessment * No more than one prior cytotoxic chemotherapy regimen (either with single or combination cytotoxic drug therapy) * One additional non-cytotoxic regimen for management of recurrent or persistent disease is allowed * Not eligi…